MTOR and lymphedema: Despite the reports on mTOR inhibitor-induced lymphedema, a clear understanding of mechanism remains to be obscure and treatment limited to cessation of the drug and to provide CDT.3, 7, 12, 15According to some reports, the benefit of stopping the mTOR inhibitor remains controversial.5, 9One of them reports reflecting the improvement based on duration used (usually within 7–30 months are mainly reversible).3In this study, until the onset of symptoms, each patient took 102, 12, and 42 months of mTOR inhibitor, respectively.